Daiwa House Industry will provide facilities that comply with Japanese regulations on regenerative medicine and will support the rapid transition from regenerative medicine research and clinical trial to commercial manufacturing. GE Healthcare contributes a series of cell processing steps that enable reproducible production of cell and gene therapy products. In addition, “FlexFactoryTMfor Cell Therapy” is introduced as a platform solution that integrates steps with a digital automation system according to customer’s needs. The non-asset business scheme can be used without “ownership” of research facilities and support the smooth start of business operations by companies. Also, in collaboration with the city of Kawasaki, open city planning is promoted that allows researchers, students, local residents, etc. to gather and exchange views, like making a “Promenade” between two neighboring existing science parks.

Nikkei Biotech news release, October 4, 2018